R. Lizambri

发表

An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP)

K. Kirito, M. Kurokawa, K. Ando, 2012, International Journal of Hematology.

Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial

J. Szer, E. Waller, G. Long, 2012, Bone Marrow Transplantation.

Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial.

W. Busse, L. Rosenwasser, M. Totoritis, 2003, The Journal of allergy and clinical immunology.

Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial

K. Kirito, M. Kurokawa, K. Ando, 2011, International journal of hematology.

Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody.

A. Gottlieb, M. Lebwohl, U. Chaudhari, 2002, Journal of the American Academy of Dermatology.

A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial.

Yoon-Koo Kang, K. Muro, R. Jain, 2015 .

Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study.

Q. Le, Yuhchyau Chen, Harold Kim, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial.

L. Cerezo, J. Giralt, M. Henke, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP),

M. Steurer, P. Boekhorst, M. Tarantino, 2011 .

Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP)

J. Viallard, I. Pabinger, J. Wasser, 2011 .

The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.

B. Chong, F. Rodeghiero, I. Pabinger, 2010 .

Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia (ITP).

R. Lyons, R. Mandanas, R. Boccia, 2009 .

Randomized Phase II Study of Palifermin for Reducing Dysphagia in Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Unresectable Non-small Cell Lung Cancer

Bartomeu Massuti, M. Krzakowski, Yuhchyau Chen, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Palifermin Reduces Severe Oral Mucositis in Subjects with Locally Advanced Head and Neck Cancer Undergoing Chemoradiotherapy

Yuhchyau Chen, K. Składowski, M. Henke, 2008 .